Abstract 1677P
Background
Chemotherapy (CT) often triggers physical and emotional changes impacting patients' lives, including their sexuality. Addressing sexual health (SH) issues is crucial for comprehensive cancer care. The aim of our study was to identify SH and intimacy issues in the Tunisian context among men undergoing CT.
Methods
The study was a cross-sectional, anonymous questionnaire-based study, conducted between March and May 2024 including 80 male cancer patients undergoing CT. Urological cancer patients were excluded. SH was evaluated by the EORTC Quality of Life Questionnaire Sexual Health (QLQ SH-22), which includes assessments of sexual satisfaction, sexual pain, sexual activity, treatment and partner-related issues. A higher score represents a higher level of symptomatology.
Results
Median age was 59.5 years [32-73]. Sixty-six patients (83%) were married and 79% were sexually active before the diagnosis. Colon cancer was the most common primary cancer (44%), followed by lung (20%) and pancreas (14%). Tumors were non metastatic in 55% of cases. The importance of communication about SH between doctors and patients was highlighted by 69% of respondents especially in those under 50 years old (95%). However, 59% considered it insufficient during checkups. The most commonly reported reason, cited by over half of patients (53%), was a lack of initiative on the part of physicians. Fifty-four patients (68%) expressed the importance of maintaining sexual activity. Yet only 33 (41%) remained sexually active during CT. Decreased libido was reported by 49 (61%) patients. Fifty-eight (73%) patients perceived a negative impact of CT on their SH. Forty-seven patients (59%) expressed dissatisfaction with communication about SH with their partners. The median sexual satisfaction score was 36 [3-60], with no correlation observed with socioeconomic status (p=0.89), educational level (p=0.09) or site of cancer (p=0.12). It was significantly higher among unmarried patients (OR=5.42, p=0.027) and in those with metastatic disease (OR=3.26, p=0.012).
Conclusions
The diagnosis and treatment of cancer significantly affect SH. Thus, providing sexual counseling to patients, especially in Arab countries where cancer and sexuality remain taboo, is essential to effectively meet their needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11